| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT07311850 Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity |
Trial sites reduced: 195 -> 170 locations |
| 2026-06-11 | NCT07575932 A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1) |
Recruitment opened |
| 2026-06-11 | NCT07575932 A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1) |
Trial sites expanded: 3 -> 48 locations |
| 2026-06-02 | NCT06924320 A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight… |
Primary endpoint(s) modified |
| 2026-06-02 | NCT06924320 A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight… |
Enrollment increased: 132 -> 381 participants |
| 2026-06-02 | NCT06924320 A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight… |
Sponsor changed: Metsera, a wholly owned subsidiary of Pfizer -> Pfizer |
| 2026-06-02 | NCT06924320 A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight… |
Trial arms changed: 5 -> 6 |
| 2026-06-02 | NCT06924320 A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight… |
date change Primary completion moved earlier: 2027-01-25 -> 2026-09-15 |
| 2026-06-02 | NCT06924320 A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight… |
date change Completion moved earlier: 2027-03-15 -> 2026-09-15 |
| 2026-05-30 | NCT06973720 A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults… |
Sponsor changed: Metsera, a wholly owned subsidiary of Pfizer -> Pfizer |
| 2026-05-30 | NCT07311850 Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity |
Sponsor changed: Metsera, a wholly owned subsidiary of Pfizer -> Pfizer |
| 2026-05-30 | NCT06712836 A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With… |
Trial completed |
| 2026-05-30 | NCT06712836 A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With… |
Sponsor changed: Metsera, a wholly owned subsidiary of Pfizer -> Pfizer |
| 2026-05-19 | NCT07400679 A Study to Learn How the Study Medicine Called PF-08653944 is Taken up Into the Blood in… |
overall status: "Recruiting" → "Active Not Recruiting" |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-05-19 | NCT07595549 A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People… | Phase 3 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07400653 | A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or… | Obesity | Recruiting |
| NCT07311850 | Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity | Obesity and Overweight | Recruiting |
| NCT07595549 | A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People… | Obesity | Not Yet Recruiting |
| Phase 2 | |||
| NCT07575932 | A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1) | Overweight | Recruiting |
| NCT06973720 | A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults… | Obesity | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT06924320 | A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight… | Obesity and Obesity-related Medical Conditions | Recruiting |
| Phase 1 | |||
| NCT07508241 | A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the… | Obesity | Recruiting |
| NCT07519135 | A Study to Learn About the Medicine Called PF-08653944 in People With and Without Reduced… | Healthy | Recruiting |
| NCT07400679 | A Study to Learn How the Study Medicine Called PF-08653944 is Taken up Into the Blood in… | Overweight | Active, Not Recruiting |